{
    "xml": "<topic id=\"PHP4675\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/risedronate-sodium\" basename=\"risedronate-sodium\" title=\"RISEDRONATE SODIUM\">\n<title>RISEDRONATE SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_903\" namespace=\"/interactions/list-of-drug-interactions/bisphosphonates/risedronate-sodium\">Risedronate Sodium</xref>\n</p>\n<data name=\"vtmid\">126136003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_819087817\" title=\"Bisphosphonates\">Bisphosphonates</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34620\" title=\"BISPHOSPHONATES\" namespace=\"/drug-classes/bisphosphonates\">BISPHOSPHONATES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP68774\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/risedronate-sodium\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Paget's disease of bone</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>30&#8239;mg daily for 2 months, course may be repeated if necessary after at least 2 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult female\">\n<p>Adult (female)</p>\n<p>5&#8239;mg daily, alternatively 35&#8239;mg once weekly.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult female\">\n<p>Adult (female)</p>\n<p>5&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of osteoporosis in men at high risk of fractures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult male\">\n<p>Adult (male)</p>\n<p>35&#8239;mg once weekly.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68838\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/risedronate-sodium\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Hypocalcaemia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68856\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/risedronate-sodium\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Atypical femoral fractures</ph>; <ph outputclass=\"caution\">oesophageal abnormalities</ph>; <ph outputclass=\"caution\">other factors which delay transit or emptying (e.g. stricture or achalasia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68759\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/risedronate-sodium\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (bisphosphonates).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68731\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/risedronate-sodium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">musculoskeletal pain</ph>; <ph outputclass=\"sideEffect\">nausea</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Duodenitis</ph>; <ph outputclass=\"sideEffect\">dysphagia</ph>; <ph outputclass=\"sideEffect\">gastritis</ph>; <ph outputclass=\"sideEffect\">oesophageal ulcer</ph>; <ph outputclass=\"sideEffect\">oesophagitis</ph>; <ph outputclass=\"sideEffect\">uveitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Atypical femoral fractures</ph>; <ph outputclass=\"sideEffect\">glossitis</ph>; <ph outputclass=\"sideEffect\">oesophageal stricture</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cutaneous vasculitis</ph>; <ph outputclass=\"sideEffect\">gastroduodenal ulceration</ph>; <ph outputclass=\"sideEffect\">hair loss</ph>; <ph outputclass=\"sideEffect\">hepatic disorders</ph>; <ph outputclass=\"sideEffect\">osteonecrosis of the jaw</ph>; <ph outputclass=\"sideEffect\">Stevens-Johnson syndrome</ph>; <ph outputclass=\"sideEffect\">toxic epidermal necrolysis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68754\" outputclass=\"pregnancy\" parent=\"/drugs/risedronate-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68866\" outputclass=\"breastFeeding\" parent=\"/drugs/risedronate-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68745\" outputclass=\"renalImpairment\" parent=\"/drugs/risedronate-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68716\" outputclass=\"monitoringRequirements\" parent=\"/drugs/risedronate-sodium\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Correct hypocalcaemia before starting.</p>\n<p>Correct other disturbances of bone and mineral metabolism (e.g. vitamin- D deficiency) at onset of treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68892\" outputclass=\"directionsForAdministration\" rev=\"1.7\" parent=\"/drugs/risedronate-sodium\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Swallow tablets whole with full glass of water; on rising, take on an empty stomach at least 30 minutes before first food or drink of the day <b>or</b>, if taking at any other time of the day, avoid food and drink for at least 2 hours before or after risedronate (particularly avoid calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids); stand or sit upright for at least 30 minutes; do not take tablets at bedtime or before rising.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68750\" outputclass=\"patientAndCarerAdvice\" rev=\"1.23\" parent=\"/drugs/risedronate-sodium\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer risedronate sodium tablets.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Oesophageal reactions</p>\n<p>Patients should be advised to stop taking the tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68700\" outputclass=\"nationalFunding\" rev=\"1.34\" parent=\"/drugs/risedronate-sodium\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA160</p>\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\r\n<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p>\r\n<p>\r\n<b>Risedronate</b> is recommended as an alternative for women:</p>\r\n<ul>\r\n<li>in whom alendronate is contra-indicated or not tolerated <b>and</b>\r\n</li>\r\n<li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA160\">www.nice.org.uk/TA160</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA161</p>\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\r\n<p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p>\r\n<p>This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.</p>\r\n<p>\r\n<b>Risedronate</b> is are recommended as an alternative for women:</p>\r\n<ul>\r\n<li>in whom alendronate is contra-indicated or not tolerated <b>and</b>\r\n</li>\r\n<li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA161\">www.nice.org.uk/TA161</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4675-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/risedronate-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74934\" title=\"Tablet\" namespace=\"/drugs/risedronate-sodium/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP98622\" namespace=\"/drugs/calcium-carbonate-with-colecalciferol-and-risedronate\" title=\"CALCIUM CARBONATE WITH COLECALCIFEROL AND RISEDRONATE\" count=\"1\" rel=\"backlink\">CALCIUM CARBONATE WITH COLECALCIFEROL AND RISEDRONATE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78314\" namespace=\"/treatment-summaries/bone-metabolism\" title=\"Bone metabolism\" count=\"1\" rel=\"backlink\">Bone metabolism</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_903\" namespace=\"/interactions/list-of-drug-interactions/bisphosphonates/risedronate-sodium\" title=\"Risedronate Sodium\" count=\"1\" rel=\"link\">Risedronate Sodium</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34620\" namespace=\"/drug-classes/bisphosphonates\" title=\"BISPHOSPHONATES\" count=\"1\" rel=\"link\">BISPHOSPHONATES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74934\" namespace=\"/drugs/risedronate-sodium/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4675",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/risedronate-sodium",
    "basename": "risedronate-sodium",
    "title": "RISEDRONATE SODIUM",
    "interactants": [
        {
            "id": "bnf_int_903",
            "label": "Risedronate Sodium"
        }
    ],
    "vtmid": "126136003",
    "drugClassification": [
        "Bisphosphonates"
    ],
    "inheritsFromClass": [
        "BISPHOSPHONATES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Paget's disease of bone",
                        "html": "Paget's disease of bone"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "30 mg daily for 2 months, course may be repeated if necessary after at least 2 months.",
                        "html": "<p>30&#8239;mg daily for 2 months, course may be repeated if necessary after at least 2 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures",
                        "html": "Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult female": [
                    {
                        "textContent": "5 mg daily, alternatively 35 mg once weekly.",
                        "html": "<p>5&#8239;mg daily, alternatively 35&#8239;mg once weekly.</p>",
                        "ageGroup": "adult (female)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women",
                        "html": "Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult female": [
                    {
                        "textContent": "5 mg daily.",
                        "html": "<p>5&#8239;mg daily.</p>",
                        "ageGroup": "adult (female)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of osteoporosis in men at high risk of fractures",
                        "html": "Treatment of osteoporosis in men at high risk of fractures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult male": [
                    {
                        "textContent": "35 mg once weekly.",
                        "html": "<p>35&#8239;mg once weekly.</p>",
                        "ageGroup": "adult (male)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Hypocalcaemia",
                "html": "Hypocalcaemia"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Atypical femoral fractures",
                "html": "Atypical femoral fractures"
            },
            {
                "type": "cautions",
                "textContent": "oesophageal abnormalities",
                "html": "oesophageal abnormalities"
            },
            {
                "type": "cautions",
                "textContent": "other factors which delay transit or emptying (e.g. stricture or achalasia",
                "html": "other factors which delay transit or emptying (e.g. stricture or achalasia"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (bisphosphonates).",
                "html": "<p>Appendix 1 (bisphosphonates).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "constipation",
                        "html": "constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "musculoskeletal pain",
                        "html": "musculoskeletal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Duodenitis",
                        "html": "Duodenitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dysphagia",
                        "html": "dysphagia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastritis",
                        "html": "gastritis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oesophageal ulcer",
                        "html": "oesophageal ulcer",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oesophagitis",
                        "html": "oesophagitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "uveitis",
                        "html": "uveitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Atypical femoral fractures",
                        "html": "Atypical femoral fractures",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "glossitis",
                        "html": "glossitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "oesophageal stricture",
                        "html": "oesophageal stricture",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Cutaneous vasculitis",
                        "html": "Cutaneous vasculitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastroduodenal ulceration",
                        "html": "gastroduodenal ulceration",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hair loss",
                        "html": "hair loss",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic disorders",
                        "html": "hepatic disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "osteonecrosis of the jaw",
                        "html": "osteonecrosis of the jaw",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Stevens-Johnson syndrome",
                        "html": "Stevens-Johnson syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "toxic epidermal necrolysis",
                        "html": "toxic epidermal necrolysis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Correct hypocalcaemia before starting.\n\nCorrect other disturbances of bone and mineral metabolism (e.g. vitamin- D deficiency) at onset of treatment.",
                "html": "<p>Correct hypocalcaemia before starting.</p><p>Correct other disturbances of bone and mineral metabolism (e.g. vitamin- D deficiency) at onset of treatment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Swallow tablets whole with full glass of water; on rising, take on an empty stomach at least 30 minutes before first food or drink of the day or, if taking at any other time of the day, avoid food and drink for at least 2 hours before or after risedronate (particularly avoid calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids); stand or sit upright for at least 30 minutes; do not take tablets at bedtime or before rising.",
                "html": "<p>Swallow tablets whole with full glass of water; on rising, take on an empty stomach at least 30 minutes before first food or drink of the day <b>or</b>, if taking at any other time of the day, avoid food and drink for at least 2 hours before or after risedronate (particularly avoid calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids); stand or sit upright for at least 30 minutes; do not take tablets at bedtime or before rising.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer risedronate sodium tablets.",
                "html": "<p>Patients or carers should be given advice on how to administer risedronate sodium tablets.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Oesophageal reactions",
                "textContent": "Patients should be advised to stop taking the tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.",
                "html": "<p>Patients should be advised to stop taking the tablets and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA160",
                        "label": "www.nice.org.uk/TA160"
                    }
                ],
                "fundingIdentifier": "NICE TA160",
                "textContent": "With oral use Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) Risedronate is recommended as an alternative for women: in whom alendronate is contra-indicated or not tolerated and who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.\n\nwww.nice.org.uk/TA160",
                "html": "<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p> <p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p> <p> <b>Risedronate</b> is recommended as an alternative for women:</p> <ul> <li>in whom alendronate is contra-indicated or not tolerated <b>and</b> </li> <li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA160\">www.nice.org.uk/TA160</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA161",
                        "label": "www.nice.org.uk/TA161"
                    }
                ],
                "fundingIdentifier": "NICE TA161",
                "textContent": "With oral use Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture. Risedronate is are recommended as an alternative for women: in whom alendronate is contra-indicated or not tolerated and who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance.\n\nwww.nice.org.uk/TA161",
                "html": "<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p> <p outputclass=\"title\">Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008)</p> <p>This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.</p> <p> <b>Risedronate</b> is are recommended as an alternative for women:</p> <ul> <li>in whom alendronate is contra-indicated or not tolerated <b>and</b> </li> <li>who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis, as indicated in the full NICE guidance.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA161\">www.nice.org.uk/TA161</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74934",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP98622",
                "label": "CALCIUM CARBONATE WITH COLECALCIFEROL AND RISEDRONATE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78314",
                "label": "Bone metabolism",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_903",
                "label": "Risedronate Sodium",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34620",
                "label": "BISPHOSPHONATES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74934",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}